As Splunk (SPLK) Share Value Rose, Holder Glynn Capital Management Has Lowered Its Stake by $636,168; Cullen Capital Management Lowered Its Merck & Co. (MRK) Holding by $7.37 Million

Merck & Co., Inc. (NYSE:MRK) Logo

Glynn Capital Management Llc decreased its stake in Splunk Inc. (SPLK) by 3.08% based on its latest 2018Q4 regulatory filing with the SEC. Glynn Capital Management Llc sold 6,117 shares as the company’s stock rose 29.02% with the market. The hedge fund held 192,717 shares of the prepackaged software company at the end of 2018Q4, valued at $20.21M, down from 198,834 at the end of the previous reported quarter. Glynn Capital Management Llc who had been investing in Splunk Inc. for a number of months, seems to be less bullish one the $18.82B market cap company. The stock increased 0.71% or $0.9 during the last trading session, reaching $127.32. About 1.94M shares traded or 3.63% up from the average. Splunk Inc. (NASDAQ:SPLK) has risen 36.60% since March 17, 2018 and is uptrending. It has outperformed by 32.23% the S&P500. Some Historical SPLK News: 24/05/2018 – SPLUNK SEES 2Q REV. $356M TO $358M, EST. $354.8M; 28/03/2018 – SPLUNK INC SPLK.O : WEDBUSH RAISES TARGET PRICE TO $103 FROM $101; 24/05/2018 – Splunk Had Seen 2019 Revenue $1.625 Billion; 24/05/2018 – SPLUNK INC SPLK.O SEES FY 2019 REVENUE ABOUT $1.645 BLN; 24/05/2018 – SPLUNK INC SPLK.O FY2019 REV VIEW $1.63 BLN — THOMSON REUTERS l/B/E/S; 22/04/2018 – DJ Splunk Inc, Inst Holders, 1Q 2018 (SPLK); 24/05/2018 – SPLUNK INC – PROMOTED TIM TULLY TO SENIOR VICE PRESIDENT, CHIEF TECHNOLOGY OFFICER; 24/05/2018 – Splunk 1Q Adj Loss/Shr 7c; 09/04/2018 – SPLUNK CLOSES PURCHASE OF PHANTOM; 24/05/2018 – SPLUNK 1Q REV. $311.6M, EST. $297.5M

Cullen Capital Management Llc decreased its stake in Merck & Co. Inc. (MRK) by 9.27% based on its latest 2018Q4 regulatory filing with the SEC. Cullen Capital Management Llc sold 96,930 shares as the company’s stock rose 5.36% with the market. The institutional investor held 948,340 shares of the health care company at the end of 2018Q4, valued at $72.46M, down from 1.05M at the end of the previous reported quarter. Cullen Capital Management Llc who had been investing in Merck & Co. Inc. for a number of months, seems to be less bullish one the $210.55B market cap company. The stock increased 0.10% or $0.08 during the last trading session, reaching $81.57. About 16.55M shares traded or 34.36% up from the average. Merck & Co., Inc. (NYSE:MRK) has risen 51.53% since March 17, 2018 and is uptrending. It has outperformed by 47.16% the S&P500. Some Historical MRK News: 02/04/2018 – Data Highlighting Advaxis’ ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting; 03/05/2018 – Merck doubles down on Moderna’s mRNA cancer vaccines, paying $125M to partner on KRAS shared antigen strategy $MRK; 19/04/2018 – P&G to buy Merck’s consumer health business for €3.4bn; 16/05/2018 – Roche immunotherapy combination increases lung cancer survival-study; 15/05/2018 – MERCK KGAA MRCG.DE SAYS SEES 2018 ADJ EBITDA FROM CONTINUING OPERATIONS IN A RANGE OF BETWEEN € 3.75BILLION AND € 4.0 BILLION; 27/03/2018 – BMY: FDA ACCEPTS OPDIVO APPLICATION FOR FOR PRIORITY REVIEW; 16/04/2018 – In CheckMate -141, Opdivo (nivolumab) Demonstrated Sustained Overall Survival (OS) Advantage over Standard of Care in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN); 24/05/2018 – Eisai And Merck Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib in First-Line Unresectable Hepatocellular Carcinoma; 09/04/2018 – KEYTRUDA® (PEMBROLIZUMAB) MONOTHERAPY MET PRIMARY ENDPOINT IN PHASE 3 KEYNOTE-042 STUDY, SIGNIFICANTLY IMPROVING OS AS FIRST-LINE THERAPY IN LOCALLY ADVANCED OR METASTATIC NSCLC PATIENTS EXPRESSING P…; 08/03/2018 – Eisai teams with Merck to boost sales of cancer drug

Cullen Capital Management Llc, which manages about $3.87 billion and $2.32 billion US Long portfolio, upped its stake in Muenchener Ruechversicherungs (MURGF) by 3,615 shares to 23,222 shares, valued at $5.07M in 2018Q4, according to the filing. It also increased its holding in Hsbc Holdings Plc (HBCYF) by 272,700 shares in the quarter, for a total of 583,533 shares, and has risen its stake in Intel Corp. (NASDAQ:INTC).

Investors sentiment decreased to 0.92 in Q4 2018. Its down 0.01, from 0.93 in 2018Q3. It dropped, as 37 investors sold MRK shares while 660 reduced holdings. 157 funds opened positions while 485 raised stakes. 1.94 billion shares or 3.54% more from 1.87 billion shares in 2018Q3 were reported. Blair William Com Il has invested 0.24% in Merck & Co., Inc. (NYSE:MRK). Cls Invs Limited Liability Co holds 0% of its portfolio in Merck & Co., Inc. (NYSE:MRK) for 852 shares. Dynamic Advisor Solutions Lc holds 0.31% of its portfolio in Merck & Co., Inc. (NYSE:MRK) for 19,858 shares. First American Bancorp holds 0.83% of its portfolio in Merck & Co., Inc. (NYSE:MRK) for 139,485 shares. Patten Gp Inc holds 25,411 shares or 0.92% of its portfolio. Platinum Invest Mgmt Limited reported 18,800 shares. Summit Wealth Advisors stated it has 33,158 shares or 0.82% of all its holdings. Cypress Cap Mgmt Ltd Llc (Wy) has 18,603 shares for 2.73% of their portfolio. White Pine Cap Limited Liability Corporation invested in 1.25% or 39,634 shares. Partnervest Advisory Limited Liability Corp accumulated 5,494 shares. Shufro Rose And Co Lc accumulated 0.17% or 19,703 shares. Rech Invsts stated it has 11.69 million shares. Forte Ltd Liability Corporation Adv holds 0.85% or 26,748 shares in its portfolio. 343,738 are owned by Hartford Management. Professional Advisory has invested 0.12% in Merck & Co., Inc. (NYSE:MRK).

More notable recent Merck & Co., Inc. (NYSE:MRK) news were published by: Forbes.com which released: “How Much Can Merck’s Share Price Grow If Keytruda Gets 10% Share Of Oncology Drug Market? – Forbes” on March 12, 2019, also Seekingalpha.com with their article: “Merck prevails in Levothyrox litigation in France – Seeking Alpha” published on March 05, 2019, Investorplace.com published: “Thursday’s Vital Data: Aurora Cannabis, Roku and Merck – Investorplace.com” on March 14, 2019. More interesting news about Merck & Co., Inc. (NYSE:MRK) were released by: Seekingalpha.com and their article: “Merck’s Keytruda flunks liver cancer study – Seeking Alpha” published on February 19, 2019 as well as Seekingalpha.com‘s news article titled: “FDA OKs expanded use for Merck’s Keytruda – Seeking Alpha” with publication date: February 16, 2019.

Analysts await Merck & Co., Inc. (NYSE:MRK) to report earnings on May, 7. They expect $1.08 earnings per share, up 2.86% or $0.03 from last year’s $1.05 per share. MRK’s profit will be $2.79B for 18.88 P/E if the $1.08 EPS becomes a reality. After $1.04 actual earnings per share reported by Merck & Co., Inc. for the previous quarter, Wall Street now forecasts 3.85% EPS growth.

Glynn Capital Management Llc, which manages about $659.77 million and $467.72M US Long portfolio, upped its stake in Microsoft Corp. (NASDAQ:MSFT) by 3,318 shares to 12,280 shares, valued at $1.25 million in 2018Q4, according to the filing. It also increased its holding in Veeva Systems Inc. (NYSE:VEEV) by 29,469 shares in the quarter, for a total of 245,077 shares, and has risen its stake in Proofpoint Inc. (NASDAQ:PFPT).

Since September 17, 2018, it had 0 insider purchases, and 11 selling transactions for $5.43 million activity. Shares for $372,151 were sold by Morgan Scott on Monday, December 10. SULLIVAN GODFREY also sold $912,100 worth of Splunk Inc. (NASDAQ:SPLK) shares. $261,103 worth of stock was sold by Carges Mark T on Monday, September 17. St. Ledger Susan sold $379,620 worth of stock. STEIN LEONARD R sold $593,839 worth of Splunk Inc. (NASDAQ:SPLK) on Monday, December 10. Another trade for 2,407 shares valued at $264,811 was made by Tully Timothy on Monday, December 10.

Investors sentiment decreased to 0.78 in 2018 Q4. Its down 0.50, from 1.28 in 2018Q3. It is negative, as 66 investors sold SPLK shares while 151 reduced holdings. 51 funds opened positions while 119 raised stakes. 134.38 million shares or 7.04% more from 125.54 million shares in 2018Q3 were reported. Winslow Evans And Crocker owns 60 shares. Tru Communication Of Vermont holds 58 shares or 0% of its portfolio. Morgan Stanley has 0.04% invested in Splunk Inc. (NASDAQ:SPLK). Citadel Ltd Liability Company stated it has 0.01% in Splunk Inc. (NASDAQ:SPLK). Cubist Systematic Strategies Ltd Company has invested 0.04% in Splunk Inc. (NASDAQ:SPLK). Balyasny Asset Management Limited Com owns 156,554 shares for 0.12% of their portfolio. Raymond James Tru Na accumulated 0.02% or 2,449 shares. 2,172 were accumulated by Winslow Cap Mngmt. 940,442 were reported by Northern Tru. Blair William And Il owns 0.16% invested in Splunk Inc. (NASDAQ:SPLK) for 215,216 shares. Chevy Chase Holding Inc holds 243,641 shares or 0.12% of its portfolio. State Of Wisconsin Inv Board owns 48,148 shares. Fred Alger Management Inc invested 0.02% in Splunk Inc. (NASDAQ:SPLK). Oppenheimer And Co Inc stated it has 0.02% in Splunk Inc. (NASDAQ:SPLK). Toth Financial Advisory reported 200 shares or 0.01% of all its holdings.

Merck & Co., Inc. (NYSE:MRK) Institutional Positions Chart